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OBJECTIVES: QoL is increasingly used as a secondary
endpoint to supplement morbidity and mortality data in
clinical trials in CHF for which regulatory bodies such as
EMEA and FDA have drafted guidelines. The aim of the
present study was to compare the draft guidelines and to
discuss their implications.
METHODS: Current guidelines from EMEA and the
FDA were reviewed and analyzed.
RESULTS: The EMEA guidelines require measurement of
12 QoL domains, whereas the FDA proposes the avoidance
of evaluating a wide array of QoL aspects. No guidance is
given with regard to the use of generic or specific question-
naires, or to requirements for psychometric properties. De-
sign issues such as duration of follow-up, or problems re-
lated to patient selection bias due to mortality and loss to
follow-up are not addressed. These differences create diffi-
culties in conducting studies accommodating both Euro-
pean and US agencies. EMEA requirements will result in ex-
actly the problems that the FDA wants to avoid (i.e.,
inclusion of all aspects of QoL in the hope that one or two
domains may be favorably affected by treatment). The rele-
vance of many of the QoL domains to elderly and incapaci-
tated CHF patients (e.g., occupational activities, sexual sat-
isfaction, interpersonal relationships) must be questioned.
CONCLUSION: The draft guidelines incorporating QoL
outcomes are welcomed. However, further and more de-
tailed guidance is required as well as a greater degree of
harmonization between the EMEA and the FDA.
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OBJECTIVE: The objective of this study was to compare
two hypertension disease management strategies.
METHODS: Uncontrolled HTN patients were identified
by ICD-9 codes from administrative data and confirmed
by chart review. Patients were randomized to 1) an Alert
group (primary care physician [PCP] and patient notifica-
tion of blood pressure results) or 2) a disease manage-
ment (DM) clinic (pharmacist-PCP co-management). In
consultation PCPs, pharmacists provided DM care utiliz-
ing evidence-based guidelines developed by a multidisci-
plinary team.
RESULTS: At baseline, there were no statistically signifi-
cant differences between groups, including systolic blood
pressure (SBP) and diastolic blood pressure (DBP), demo-
graphics, comorbidities, and anti-hypertensive medica-
tion costs. By intention-to-treat analysis the DM group
had significant reductions in SBP and DBP at 6 and 12
months (SBP/DBP: 22mmHg/9mmHg [n  78] and
22mmHg/4mmHg [n  58], respectively, p  0.01),
compared to baseline. At 18 months, the SBP reduction
was statistically significant (21mmHg [n  31], p 
0.01), but DBP reduction was not (3mmHg). The Alert
group had significant reductions in SBP and DBP at 6,
12, and 18 months (SBP/DBP: 10mmHg/7mmHg
[n  92], 11mmHg/8mmHg [n  81], 11mmHg/
7mmHg [n  39], respectively, p  0.01) compared to
baseline. The reductions in SBP were significantly greater
in the DM group than in the Alert group at 6 and 12
months (22mmHg versus 10mmHg and 22mmHg
versus 11mmHg, p  0.01), but not at 18 months. Dif-
ferences in DBP were not statistically significant. At 12
and 18 months, per-member per-month DM group visit
costs were significantly lower than those of the Alert
group ($12 versus $16, p  0.01; $11 versus $17, p 
0.05, respectively).
CONCLUSIONS: These results suggest that clinically im-
portant BP reductions may be achieved cost-effectively in
a hypertension disease management program.
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OBJECTIVE: The purpose of this study was to evaluate
the cost-effectiveness of tissue plasminogen activator (t-
PA) compared to streptokinase in the treatment of acute
myocardial infarction.
METHODS: The data for this study were obtained from
the GUSTO trial (1972–1992), which is the largest and
the most comprehensive clinical trial studying the two
drugs under investigation, and from other studies that an-
alyzed the data from the GUSTO trial. The GUSTO trial
randomly assigned 41,021 patients around the world to
four different thrombolytic therapies; we focused on the
patients that received t-PA and streptokinase. Inclusion
criteria were requirements of signs and symptoms of myo-
